Northern Plains Laboratory, LLC

Northern Plains Laboratory, LLC was paid $1.16M by Medicaid between Jan 2018 and Dec 2024, across 71 billing codes. Its largest line is 87491, Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe — 9.7% of everything it billed.

33Billing provider infoNORTHERN PLAINS LABORATORY, LLC
BISMARCK, ND 58501

33aNPI1174504989assigned 11/09/2005

33bProvider typeClinical Medical Laboratory

28Total paid$1.16M

24GClaims87,845

24DCodes billed71

24AFirst – last monthJan 2018 – Dec 2024

Compared with peers

Next to other Clinical Medical Laboratory providers in North Dakota

Rank by total paid#4 of 15

Median peer was paid$4K

This provider vs. median286×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	12,924	$163K
2019	10,719	$143K
2020	9,995	$149K
2021	15,059	$218K
2022	15,216	$187K
2023	14,608	$183K
2024incomplete	9,324	$114K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	9.7%	2,522	2,404	$112K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	7.2%	2,516	2,400	$83K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	6.3%	1,735	1,634	$73K
84443	Thyroid stimulating hormone (TSH)	6.0%	3,850	3,632	$69K
80061	Lipid panel	5.8%	3,514	3,335	$67K
80053	Comprehensive metabolic panel	5.4%	6,519	5,969	$63K
80050	General health panel	4.9%	1,187	1,144	$56K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	4.5%	1,527	1,448	$52K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	4.4%	8,130	7,381	$51K
87480		4.1%	2,125	1,991	$48K
87510		3.5%	2,116	1,984	$40K
87660		3.4%	2,113	1,981	$40K

59 more codes

36415	Collection of venous blood by venipuncture	3.3%	10,216	$38K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	2.8%	1,384	$32K
0241U	Neonatal screening for hereditary disorders, genomic sequence analysis panel	2.8%	246	$32K
87086	Culture, bacterial; quantitative colony count, urine	2.6%	4,056	$30K
83036	Hemoglobin; glycosylated (A1C)	2.1%	3,260	$24K
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	1.9%	1,481	$22K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	1.9%	439	$22K
87070		1.8%	2,504	$21K
82607		1.7%	1,387	$19K
81001		1.2%	4,704	$14K
80048	Basic metabolic panel (calcium, ionized)	1.2%	1,683	$13K
82728		1.1%	1,108	$12K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	1.0%	762	$12K
84439		<1%	1,802	$11K
81003		<1%	3,947	$8K
87186		<1%	1,026	$8K
80081		<1%	103	$8K
86140		<1%	1,520	$7K
87653		<1%	204	$7K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	<1%	87	$6K
84481		<1%	525	$6K
83550		<1%	948	$6K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	298	$5K
83540		<1%	993	$5K
81025		<1%	584	$5K
86592		<1%	828	$3K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	16	$3K
87147		<1%	422	$2K
82950		<1%	436	$2K
83735		<1%	372	$2K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	30	$2K
86803		<1%	233	$2K
82570		<1%	377	$2K
84702		<1%	169	$1K
87077		<1%	152	$1K
87088		<1%	176	$1K
85018		<1%	396	$1K
83655		<1%	65	$832.87
82043		<1%	121	$635.26
86850		<1%	53	$520.39
85027		<1%	86	$427.07
87081		<1%	55	$385.01
87807		<1%	29	$351.62
87205		<1%	78	$331.70
84703		<1%	40	$318.17
82746		<1%	12	$260.70
83001		<1%	13	$245.35
85610		<1%	60	$189.68
87340		<1%	13	$155.54
85652		<1%	44	$122.85
83690		<1%	13	$75.79
80076		<1%	12	$73.53
85004		<1%	13	$14.36
86694		<1%	121	$13.50
82947		<1%	18	$13.11
86696		<1%	85	$9.08
86695		<1%	85	$6.19
85048		<1%	13	$5.64
G0471	Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha)	0%	88	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSCHLEY, KURT (GOVERNOR)